<<
>>

Introduction

Cardiac illness related to human immunod­eficiency virus (HIV) infection tends to occur late in the disease course and is there­fore becoming more prevalent as therapy of the viral infection and longevity improve.

Autopsy series and retrospective analyses performed before the introduction of highly active antiretroviral therapy (HAART) regi­mens suggest that cardiac lesions are pres­ent in 25-75% of patients with acquired immunodeficiency syndrome (AIDS) [1]. HAART regimens have significantly modi­fied the course of HIV disease, with longer survival rates and improvement of life qual­ity in HIV-infected subjects expected. How­ever, early data raised concerns about HAART being associated with an increase in both peripheral and coronary arterial dis­eases. HAART is only available to a minori­ty of HIV-infected individuals worldwide, and studies prior to HAART therapy remain globally applicable. As 36.1 million adults and children are estimated to be living with HIV/AIDS and 5.3 million adults and chil­dren are estimated to have been newly infected with HIV during the year 2000 [2], HIV-associated symptomatic heart failure may become one of the leading causes of heart failure worldwide. A variety of poten­tial etiologies have been postulated for HIV- related heart disease, including myocardial infection with HIV itself, opportunistic infections, viral infections, autoimmune response to viral infection, drug-related car­diotoxicity, nutritional deficiencies, and prolonged immunosuppression (Table 1).

<< | >>
Source: Barbaro Giuseppe, Boccara Franc (eds.). Cardiovascular Disease in AIDS. 2nd edition. — Springer,2009. — 169 p.. 2009
More medical literature on Medic.Studio

More on the topic Introduction: